Summary In patients with advanced head and neck squamous cell carcinoma (HNSC), evidence of cellmediated immunity and monocyte functional abnormalities has been reported. We studied the production of interleukin 1 beta (IL-lbeta) and interleukin 6 (IL-6) by peripheral blood monocytes from 22 patients with HNSC (12 larynx and ten oral cavity cancers) in comparison with monocyte cytokine production of age-matched healthy subjects. Pure monocytes were incubated with and without lipopolysaccarides (LPS) (10 1tg ml-') for 4 h at 37C and IL-Ibeta and IL-6 concentrations were determined in supernatants by specific ELISA. There was no significant difference in IL-1beta levels in monocyte supernatants from cancer in comparison to control subjects; conversely, a higher IL-6 production by unstimulated and LPS-activated cells from HNSC patients than from controls was found. No relationship was observed between cytokine production and cancer stage. The regression analysis evidenced a significant correlation between IL-lbeta and IL-6 monocyte-release in HNSC patients and in controls, so suggesting a possible autocrine control of IL-6 production by other cytokines.
Interleukin-lbeta and interleukin-6 release by peripheral blood Summary In patients with advanced head and neck squamous cell carcinoma (HNSC), evidence of cellmediated immunity and monocyte functional abnormalities has been reported. We studied the production of interleukin 1 beta (IL-lbeta) and interleukin 6 (IL-6) by peripheral blood monocytes from 22 patients with HNSC (12 larynx and ten oral cavity cancers) in comparison with monocyte cytokine production of age-matched healthy subjects. Pure monocytes were incubated with and without lipopolysaccarides (LPS) (10 1tg ml-') for 4 h at 37C and IL-Ibeta and IL-6 concentrations were determined in supernatants by specific ELISA. There was no significant difference in IL-1beta levels in monocyte supernatants from cancer in comparison to control subjects; conversely, a higher IL-6 production by unstimulated and LPS-activated cells from HNSC patients than from controls was found. No relationship was observed between cytokine production and cancer stage. The regression analysis evidenced a significant correlation between IL-lbeta and IL-6 monocyte-release in HNSC patients and in controls, so suggesting a possible autocrine control of IL-6 production by other cytokines.
Cells of monocyte lineage and their soluble products play vital roles in the integration of host immunity by providing the necessary signals for B-and T-lymphocytes, and for host non-specific immune activation (Evans et al., 1983) . In fact, the mononuclear phagocyte has been demonstrated to be involved at the initiation of the immune response as an antigen-presenting cell or as a source of a variety of cytokines, such as interleukin-Ibeta (IL-lbeta) and interleukin-6 (IL-6) (Unanue, 1984; Schindler et al., 1990) . These are pleiotropic monokines with several common and well-distinguished biological properties. IL-lbeta is involved in many host reactions including immunologic, inflammatory, endocrinologic and haemopoietic ones (Dinarello, 1988) . Furthermore, IL-lbeta performs a synergistic role in potentiating natural killer cell and macrophage-mediated tumour lysis (Matsushima et al., 1987) . IL-lbeta itself has also a direct antiproliferative or cytocidal effect on several tumour cell lines and it primarily promotes the actions of other cytokines (Tumour Necrosis Factor-TNF and IL-6) on cancer cells (Morinaga et al., 1989) . On the other hand IL-6 has a variety of functions including B-cell-stimulating activity (Muraguchi et al., 1985) , and promotion of plasmocytoma growth (Van Damme et al., 1987) . Some of its activities are shared with IL-lbeta. IL-lbeta and IL-6 both act as inducers of hepatic acute phase proteins (Gauldie et al., 1987) and as 'haematopoietin-l' (Takai et al., 1988) .
Some clinical and animal studies have evidenced an altered capacity of monocytes from cancer patients to synthesise IL-lbeta (Ikemoto et al., 1990; Pollack et al., 1983; Herman et al., 1984) , and recently we reported an increased IL-6 serum level and monocyte production in cancer patients (Gallo et al., 1992) .
Based on these data and on the well-known impaired cytotoxicity and cytokine-production in peripheral blood mononuclear cells from head and neck cancer (Walter et al., 1985; Beauchamp et al., 1988; Wanebo et al., 1988) , we investigated IL-l beta and IL-6 spontaneous and (LPS)-stimulated production by freshly isolated blood monocytes from patients with advanced head and neck squamous cancer (HNSC) in comparison to healthy subjects.
Material and methods
The study was carried out on 22 male patients aged between 49 and 67 years (mean age 58.9 years) with carcinoma of the larynx (n = 12) and of the oral cavity (n = 10); tumour stages were classified according to UICC (1978) (Table I ). Our study included all patients with primary head and neck cancer; they did not receive chemotherapy before the admission to the study; no patient received anti-inflammatory drugs during the preceding 2 weeks. 22 age-matched healthy subjects were also studied; all subjects were free from infections and from any drug in the 2 weeks preceding blood sampling. Blood samples were withdrawn from fasting subjects between 8 and 9 am, 2-3 days before surgery.
Cell preparation Mononuclear cells were separated from peripheral blood, drawn in plastic syringes and anticoagulated with citrate (1:9 T3NIMO  T3NIMO  T2NOMO  T2NOMO  T3NOMO  T3N1MO  TINOMO  T2NOMO  T3NOMO  TINOMO  T3NOMO  T2NOMO  T3NIMO  T4NIMO  TINOMO  T3NOMO  T3N1MO  TINOMO  T3NOMO  T4NOMO  T2NOMO  T3NIMO   Stage  IV  IV   II   II   III  IV  I  II  III  I  III   II   IV  IV  I  III  IV   I  III  IV  II  IV Correspondence: 0. Gallo 
and centrifuged at 120g for 10min and platelets were removed. After dilution 1:2 with PBS, cells were layered into FicollHypaque (Lymphoprep, Immuno, Austria) and centrifuged at 400 g for 20 min at 22°C (Boyum, 1976 453.9 ± 105.1 vs 425.1 ± 146.8 pg 10-6 cells for IL-lbeta and IL-6 level, respectively). A positive regression between IL-6 and IL-lbeta production by LPS stimulated monocytes was found both in patients (r = 0.85, P <0.0001) and in controls (r= 0.65, P=0.001) (Figure 3 ).
Discussion
In this study we reported that cytokine production by monocytes is altered in patients with head and neck cancer in comparison to healthy subjects. An increased production of IL-6 by monocytes from cancer patients was observed in both unstimulated and LPS stimulated cells. Conversely, freshly isolated monocytes from both groups did not release detectable amounts of IL-lbeta in the absence of stimulation and the increase in the release of this monokine after exposure to LPS was similar in cancer patients and controls.
The finding that monocytes from HNSC did not show any substantial differences in IL-1 beta production when compared with IL-lbeta release from controls, is in accordance with previous reports in patients affected by different neoplasms (Economou et al., 1988; Arnould et al., 1988; Erroi et al., 1989) . At variance are the results from other authors (Ikemoto et al., 1990; Herman et al., 1984; Pollack et al., 1983) who found an altered capacity of monocytes to synthesise IL-lbeta.
The increased IL-6 release by monocytes in HNSC patients could be related to a functional activation of monocytes in the host or to induction of this cytokine by other cytokines, such as IL-lbeta and TNF-alpha. In fact, IL-lbeta and TNF 1000- 
Results
Human monocytes freshly isolated from both cancer and healthy subjects did not produce detectable amounts of ILlbeta after 4-h-incubation in the absence of stimuli; neither did unstimulated blood monocytes from controls release appreciable amounts of IL-6, whereas in five of 22 cancer patients small amounts (87.5 ± 14.8 pg 10-6 cells) of spontaneously released IL-6 were detected.
Upon LPS-stimulation for 4 h, IL-lbeta and IL-6 were produced by monocytes from both cancer patients and healthy subjects in detectable amounts: IL-lbeta production by LPS stimulated monocytes was found to be without any significant difference between cancer patients and controls (240.1 ± 37 vs 232.1 ± 49.4 pg 10-6 cells, respectively) ( Figure   1 ). In contrast, IL-6 production by LPS stimulated monocytes from HNSC patients was significantly higher (P <0.05) than that of controls (438.2 ± 91.2 and 54.7 ± 9.9 pg 10-6 cells, respectively) and 15 of 22 patients showed IL-6 production out of the control range (Figure 2) .
IL-lbeta and IL-6 release from monocytes of cancer subjects with or without LPS stimulation, did not evidence any statistically significant difference in relation to cancer stage (I-IIvs III-IV Stage: 274.3 ± 36.9 vs 251.7 ± 55.5; and Figure 3 Relationship between IL-lbeta and IL-6 monocyte production upon LPS stimulation in cancer patients and in control subjects.
may regulate IL-6 production in monocytes and in other cells (Tosato et al., 1990; Kohase et al., 1986) . In our study IL-lbeta has not been found higher in patients than in controls, but we should consider that IL-6, in its turn, inhibits IL-lbeta production (Schindler et al., 1990) . Hence, a key role in the increased IL-6 production might be played by TNF-alpha, which induces appearance of IL-6 in peripheral blood when administered in vivo (Jablons et al., 1988) . Interestingly, we have previously observed an increased TNFalpha production by peripheral blood monocytes in HNSC (Gallo et al., 1991) possibly induced by tumour cell membrane costituents (Jaemcke et al., 1990 ).
In conclusion, our study demonstrated that the tumour bearing state may induce an altered cytokine release from peripheral blood monocytes characterised by an increased IL-6 production. Since IL-6 has multiple known biological effects including systemic control of hepatic acute phase protein synthesis, activation of T-B-and NK-cells, and effects on the adrenocorticoid axis (Hirano et al., 1990) , the high IL-6 release by monocytes may be one of the mechanisms underlying the host's immune and metabolic response to malignancy in these cancer patients.
